Oxaliplatin serves as a basic therapeutic agent for various malignant tumors.Oxaliplatin-induced hypersensitivity reactions are potentially life-threatening,and frequently lead to treatment discontinuation.Alternative therapies may be less effective and/or more expensive,with varying tolerability.Oxaliplatin hypersensitivity reactions typically manifest as a classic type Ⅰ allergy,as well as cytokine release reactions and mixed types.In clinical practice,management of anaphylaxis and questions relative to rechallenge with oxaliplatin after occurrence of hypersensitivity reactions are of utmost concern.Therefore,based on evidence-based medicine and clinical practice experience,the expert panel carried out a comprehensive assessment and discussion on the definition,clinical characteristics,diagnosis,classification and grading criteria,management,and rechallenge of hypersensitivity reactions to oxaliplatin.Eventually,the"Chinese expert consensus on whole-process management of oxaliplatin-induced hypersensitivity reactions(2024 edition)"was formulated to further standardize the whole-process management of oxaliplatin-induced hypersensitivity reactions.The consensus has been registered on Practice guideline REgistration for transPAREncy(PREPARE)with the registration number PREPARE-2024CN371.